; and (3) an appropriate timeline for the Drug Affordability and Access Committee to determine the reasonableness of a drug’s manufacturer list price and retail price to be in effect the second year after coming to market. (b) Report Any contract between the Secretary and the Academy under this section shall include a requirement that the Academy submit a report on the results of the study described in subsection (a) to the Secretary, the Drug Affordability and Access Committee, and Congress. 5. Drug Affordability and Access Committee (a) Establishment There is hereby authorized to be established a nonprofit corporation to be known as the Drug Affordability and Access Committee (referred to in this section as the Committee ), which is neither an agency nor establishment of the United States Government. The Committee shall be headed by an Executive Director. (b) Purpose The purpose of the Committee is to determine a reasonable manufacturer list price and retail price for each applicable drug. (c) Board of Directors (1) In general The Committee shall have a Board of Directors, which shall be composed of ex officio and appointed members in accordance with this subsection. All appointed members of the Board shall be voting members. (2) Ex officio members The non-voting ex officio members of the Committee shall be the following individuals or their designees: (A) The Secretary of Health and Human Services. (B) The Director of the National Institutes of Health. (C) The Commissioner of Food and Drugs. (D) The Director of the Agency for Healthcare Research and Quality. (E) The Director of the Centers for Disease Control and Prevention. (F) The Administrator of the Centers for Medicare & Medicaid Services. (G) The Assistant Secretary for Planning and Evaluation. (3) Appointed members (A) In general Ten additional members shall be appointed to the Committee by the Comptroller General of the United States not later than 180 days after the date of enactment of this Act. Such members shall include— (i) 2 patient and consumer